In the latest session, BridgeBio Pharma Inc. (NASDAQ: BBIO) closed at $13.81 down -3.09% from its previous closing price of $14.25. In other words, the price has decreased by -$0.44 from its previous closing price. On the day, 2088479 shares were traded. BBIO stock price reached its highest trading level at $14.31 during the session, while it also had its lowest trading level at $13.71.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Ratios:
For a deeper understanding of BridgeBio Pharma Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.50 and its Current Ratio is at 4.50.
Upgrades & Downgrades
On December 27, 2021, SVB Leerink reiterated its Outperform rating and also upped its target price recommendation from $66 to $24.
Mizuho reiterated its Buy rating for the stock on December 27, 2021, while the target price for the stock was revised from $86 to $25.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 03 when Kumar Neil sold 120,000 shares for $10.96 per share. The transaction valued at 1,315,224 led to the insider holds 1,252,722 shares of the business.
STEPHENSON BRIAN C sold 62,692 shares of BBIO for $687,148 on Mar 03. The Secretary, Treasurer & CFO now owns 156,837 shares after completing the transaction at $10.96 per share. On Feb 17, another insider, Kumar Neil, who serves as the CEO and President of the company, sold 44,798 shares for $12.70 each. As a result, the insider received 569,073 and left with 4,813,197 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 29.56.
Stock Price History:
Over the past 52 weeks, BBIO has reached a high of $19.94, while it has fallen to a 52-week low of $4.98. The 50-Day Moving Average of the stock is 10.92, while the 200-Day Moving Average is calculated to be 9.95.
Shares Statistics:
For the past three months, BBIO has traded an average of 2.58M shares per day and 7.64M over the past ten days. A total of 149.37M shares are outstanding, with a floating share count of 107.05M. Insiders hold about 4.30% of the company’s shares, while institutions hold 98.10% stake in the company. Shares short for BBIO as of Jan 30, 2023 were 18.65M with a Short Ratio of 16.75M, compared to 19M on Dec 29, 2022. Therefore, it implies a Short% of Shares Outstanding of 12.48% and a Short% of Float of 22.33%.
Earnings Estimates
There are 9 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.85 for the current quarter, with a high estimate of -$0.71 and a low estimate of -$1.14, while EPS last year was -$1.01. The consensus estimate for the next quarter is -$0.85, with high estimates of -$0.7 and low estimates of -$0.94.
Analysts are recommending an EPS of between -$3.05 and -$3.48 for the fiscal current year, implying an average EPS of -$3.21. EPS for the following year is -$3.13, with 9 analysts recommending between -$2.42 and -$3.68.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for BBIO’s current fiscal year. The highest revenue estimate was $101.26M, while the lowest revenue estimate was $75.78M, resulting in an average revenue estimate of $80.34M. In the same quarter a year ago, actual revenue was $69.72M, up 15.20% from the average estimate.
